Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
33
IGC Quote, Financials, Valuation and Earnings
Last price:
$0.35
Seasonality move
:
82.76%
Day range:
$0.32 - $0.35
52-week range:
$0.25 - $0.50
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
20.11x
P/B ratio:
4.43x
Volume:
2.2M
Avg. volume:
4.8M
1-year change:
-25.61%
Market cap:
$28M
Revenue:
$1.3M
EPS (TTM):
-$0.11
Analysts' Opinion
-
Consensus RatingIGC Pharma has received a consensus rating of Buy. The company's average rating is a Buy based on 2 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $3.88, IGC Pharma has an estimated upside of 1059.83% from its current price of $0.33.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $3.50 representing 100% downside risk from its current price of $0.33.
Fair Value
-
According to the consensus of 2 analysts, IGC Pharma has 1059.83% upside to fair value with a price target of $3.88 per share.
IGC vs. S&P 500
-
Over the past 5 trading days, IGC Pharma has underperformed the S&P 500 by -8.77% suggesting its relative strength compared to the major market average is weak at this time.
Share Buyback
-
IGC Pharma does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
IGC Pharma has grown year-over-year revenues for 3 quarters straight. In the most recent quarter IGC Pharma reported revenues of $257K.
Earnings Growth
-
IGC Pharma has grown year-over-year earnings for 1 quarter straight. In the most recent quarter IGC Pharma reported earnings per share of -$0.02.
Enterprise value:
27.8M
EV / Invested capital:
--
Price / LTM sales:
20.11x
EV / EBIT:
--
EV / Revenue:
21.84x
PEG ratio (5yr expected):
--
EV / Free cash flow:
-5.26x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
$636K
Return On Assets:
-86.02%
Net Income Margin (TTM):
-712.7%
Return On Equity:
-116.24%
Return On Invested Capital:
-114.2%
Operating Margin:
-730.74%
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | $912K | $1.3M | $1.3M | $295K | $330K | |
| Gross Profit | $442K | $733K | $619K | $171K | $154K | |
| Operating Income | -$11.6M | -$9.8M | -$7.4M | -$2.2M | -$1.4M | |
| EBITDA | -$11M | -$9.2M | -$6.8M | -$2M | -$1.3M | |
| Diluted EPS | -$0.22 | -$0.22 | -$0.08 | -$0.04 | -$0.01 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | $23.5M | $15.1M | $6.5M | $3.7M | $2.9M | |
| Total Assets | $35.9M | $26.8M | $17.2M | $9.9M | $8.7M | |
| Current Liabilities | $2.4M | $2.4M | $1.9M | $2.3M | $2.3M | |
| Total Liabilities | $3.1M | $2.9M | $2.3M | $2.6M | $2.4M | |
| Total Equity | $32.8M | $23.9M | $14.9M | $7.3M | $6.3M | |
| Total Debt | $580K | $144K | $141K | $137K | $134K | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$7M | -$5.2M | -$4.8M | -$526K | -$730K | |
| Cash From Investing | -$235K | -$317K | -$442K | -$323K | -$142K | |
| Cash From Financing | $100K | $3.5M | $4.5M | $667K | $805K | |
| Free Cash Flow | -$7.7M | -$5.7M | -$5.3M | -$851K | -$896K | |
IGC
Sector
Market Cap
$28M
$34.4M
Price % of 52-Week High
67.09%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
-16.42%
-1.01%
1-Year Price Total Return
-25.61%
-37.36%
Beta (5-Year)
1.452
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Sell
Level
$0.36
200-day SMA
Sell
Level
$0.33
Bollinger Bands (100)
Buy
Level
0.29 - 0.33
Chaikin Money Flow
Buy
Level
26.9M
20-day SMA
Sell
Level
$0.33
Relative Strength Index (RSI14)
Buy
Level
51.61
ADX Line
Buy
Level
30.68
Williams %R
Neutral
Level
-78.3333
50-day SMA
Buy
Level
$0.32
MACD (12, 26)
Buy
Level
0.10
25-day Aroon Oscillator
Buy
Level
64
On Balance Volume
Neutral
Level
72.8M
Financial Scores
Sell
Altman Z-Score
(Annual)
Level (-16.1798)
Sell
CA Score
(Annual)
Level (-2.947)
Buy
Beneish M-Score
(Annual)
Level (-3.672)
Buy
Momentum Score
Level (2)
Sell
Ohlson Score
Level (8.3578)
Buy
Piotroski F Score
(Annual)
Level (4)
Sell
Quality Ratio Score
Level (1)
Sell
Fundamental Score
Level (3)
Revenue Forecast
Earnings per Share Forecast
Company Profile
IGC Pharma Inc develops cannabinoid-based formulations for treating diseases and conditions, including, but not limited to, Alzheimer’s disease, period cramps, premenstrual syndrome, and chronic pain. The company has investigational drug assets targeting Alzheimer’s disease, IGC-AD1, IGC-M3, IGC-1C, and TGR-63, which have demonstrated in Alzheimer’s cell lines the potential to be effective in suppressing or ameliorating key hallmarks of Alzheimer’s disease, such as plaques or tangles.
Stock Forecast FAQ
In the current month, IGC has received 2 Buy ratings 0 Hold ratings, and 0 Sell ratings. The IGC average analyst price target in the past 3 months is $3.88.
-
Where Will IGC Pharma Stock Be In 1 Year?
According to analysts, the consensus estimate is that IGC Pharma share price will rise to $3.88 per share over the next 12 months.
-
What Do Analysts Say About IGC Pharma?
Analysts are divided on their view about IGC Pharma share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that IGC Pharma is a Sell and believe this share price will drop from its current level to $3.50.
-
What Is IGC Pharma's Price Target?
The price target for IGC Pharma over the next 1-year time period is forecast to be $3.88 according to 2 Wall Street analysts, 2 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is IGC A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for IGC Pharma is a Buy. 2 of 2 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of IGC?
You can purchase shares of IGC Pharma via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase IGC Pharma shares.
-
What Is The IGC Pharma Share Price Today?
IGC Pharma was last trading at $0.35 per share. This represents the most recent stock quote for IGC Pharma. Yesterday, IGC Pharma closed at $0.33 per share.
-
How To Buy IGC Pharma Stock Online?
In order to purchase IGC Pharma stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
